Bausch Health Companies (TSE:BHC) Issues Quarterly Earnings Results

Bausch Health Companies (TSE:BHC) posted its earnings results on Wednesday. The company reported C$1.79 earnings per share for the quarter, FiscalAI reports. Bausch Health Companies had a positive return on equity of 120.43% and a negative net margin of 13.54%.The company had revenue of C$2.85 billion during the quarter.

Bausch Health Companies Trading Up 2.5%

Shares of Bausch Health Companies stock traded up C$0.16 during trading on Wednesday, hitting C$6.56. The company’s stock had a trading volume of 713,739 shares, compared to its average volume of 477,941. The stock has a market cap of C$2.45 billion, a price-to-earnings ratio of -2.02, a price-to-earnings-growth ratio of 0.21 and a beta of 0.97. Bausch Health Companies has a 52 week low of C$6.10 and a 52 week high of C$11.97. The stock has a 50-day moving average price of C$6.98 and a two-hundred day moving average price of C$7.60. The company has a debt-to-equity ratio of -1,009.96, a current ratio of 1.32 and a quick ratio of 0.58.

Key Headlines Impacting Bausch Health Companies

Here are the key news stories impacting Bausch Health Companies this week:

• Positive Sentiment: Elidel (pimecrolimus) cream is now reimbursed under Alberta’s public drug plan for eligible patients with mild to moderate atopic dermatitis. Improved insurance coverage could expand patient access and support demand for the product, although the company did not provide a financial impact estimate. Elidel reimbursement announcement
• Neutral Sentiment: The Alberta reimbursement decision is a product-level development rather than a change to Bausch Health’s overall earnings guidance. Investors will likely need additional sales data to determine whether it meaningfully affects revenue or cash flow.
• Negative Sentiment: Zacks Research reduced its estimates across several future periods. FY2027 EPS was lowered to $5.06 from $5.10, FY2028 EPS to $4.26 from $4.34, Q2 2027 EPS to $1.15 from $1.16, Q3 2027 EPS to $1.46 from $1.47, Q4 2027 EPS to $1.32 from $1.33, and Q2 2028 EPS to $1.14 from $1.16. These small but broad cuts imply slightly weaker expected profitability and may weigh on the shares.
• Negative Sentiment: The revisions reverse the more optimistic changes Zacks made a few days earlier, when it raised estimates for Q3 2026, FY2027 and FY2028. The current full-year consensus estimate remains $5.55 per share, so the latest cuts create a less favorable outlook relative to recent forecasts.

Analyst Upgrades and Downgrades

Separately, Jefferies Financial Group raised Bausch Health Companies to a “hold” rating in a report on Wednesday, July 22nd. Three analysts have rated the stock with a Hold rating, Based on data from MarketBeat, Bausch Health Companies presently has an average rating of “Hold”.

About Bausch Health Companies

Bausch Health Companies Inc (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors.